Overview

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cincinnati
Treatments:
Fluorouracil
Folfirinox
Gemcitabine
Irinotecan
Oxaliplatin
Paclitaxel